Bausch Health Companies Inc (BHC)

Apr 21, 2025

BofA Cuts Price Target on Bausch Health to $5 From $7 - marketscreener.com

Apr 21, 2025

Apr 21, 2025

TSX falls as Trump's Fed criticism shakes markets - marketscreener.com

Apr 21, 2025

Apr 21, 2025

Bausch (BHC) Moves 13.3% Higher: Will This Strength Last? - Nasdaq

Apr 21, 2025

Apr 20, 2025

Analysts Expect Bausch Health Companies Inc. (NYSE:BHC) To Breakeven Soon - simplywall.st

Apr 20, 2025

Apr 19, 2025

Press Release Distribution & PR Platform - ACCESS Newswire

Apr 19, 2025

Apr 19, 2025

Is Bausch Health Companies (BHC) the Ridiculously Cheap Stock to Invest in? - Yahoo Finance

Apr 19, 2025

Apr 19, 2025

11 Ridiculously Cheap Stocks to Invest in - Insider Monkey

Apr 19, 2025

Apr 17, 2025

Bausch Health Provides Update on Solta Medical - marketscreener.com

Apr 17, 2025

Apr 17, 2025

U.S. District Court Rules in Favor of Bausch Health and FDA in XIFAXAN Case - TipRanks

Apr 17, 2025

Apr 17, 2025

Bausch Health shares jump on favorable court ruling By Investing.com - Investing.com South Africa

Apr 17, 2025

Apr 17, 2025

Bausch Health shares jump on favorable court ruling - Investing.com

Apr 17, 2025

Apr 17, 2025

Bausch says court grants summary judgment in favor of FDA, Salix, and Teva - TipRanks

Apr 17, 2025

Apr 17, 2025

Major Legal Win: How Bausch Health's Court Victory Protects Billion-Dollar XIFAXAN Franchise Until 2028 - Stock Titan

Apr 17, 2025

Apr 17, 2025

Fitch raises Bausch Health rating to CCC+ amid refinancing By Investing.com - Investing.com Canada

Apr 17, 2025

Apr 17, 2025

Fitch raises Bausch Health rating to CCC+ amid refinancing - Investing.com

Apr 17, 2025

Apr 17, 2025

Fitch Upgrades Bausch + Lomb, Bausch Health But Keeps Both Junk - Bloomberg.com

Apr 17, 2025

Apr 16, 2025

Topical Drug Delivery Market Set to Witness Significant Growth - openPR.com

Apr 16, 2025

Apr 16, 2025

Verteporfin Market Generated Opportunities, Future Scope - openPR.com

Apr 16, 2025

Apr 15, 2025

Bausch Health Companies IncAdopts Shareholder Rights PlanSEC Filing - marketscreener.com

Apr 15, 2025

Apr 15, 2025

Scar Treatment Market Set to Witness Significant Growth - openPR.com

Apr 15, 2025

Apr 14, 2025

Bausch Health Adopts Shareholder Rights Plan to Ensure Fair Treatment - TipRanks

Apr 14, 2025

Apr 14, 2025

Bausch Health Announces Adoption of Shareholder Rights Plan - The Joplin Globe

Apr 14, 2025

Apr 14, 2025

Bausch Health's New Poison Pill Defense: Key Details of Shareholder Protection Strategy - Stock Titan

Apr 14, 2025

Apr 14, 2025

The most oversold and overbought stocks on the TSX - The Globe and Mail

Apr 14, 2025

Apr 14, 2025

Bausch Health Responds to Norwich Pharmaceuticals Tentative FDA Approval for a 200 mg Rifaximin - marketscreener.com

Apr 14, 2025

Apr 14, 2025

Intraocular Lens Market Overall Study Report 2025-2032 | Bausch - openPR.com

Apr 14, 2025

Apr 10, 2025

Bausch Health Announces Ortho Dermatologics 2025 ASPIRE HIGHER Scholarship Program - ACCESS Newswire

Apr 10, 2025

Apr 10, 2025

New $10K Scholarship Program Empowers Students Affected by Skin Conditions - Stock Titan

Apr 10, 2025

Apr 09, 2025

Bausch Health secures intent for acne treatment coverage By Investing.com - Investing.com South Africa

Apr 09, 2025

Apr 09, 2025

Atopic Dermatitis Pipeline 2025: Therapies Under - openPR.com

Apr 09, 2025

Apr 09, 2025

Bausch Health signs LOI with pan-Canadian Pharmaceutical Alliance for CABTREO - TipRanks

Apr 09, 2025

Apr 09, 2025

Bausch Health Canada signs Cabtreo public drug plan coverage letter of intent - TipRanks

Apr 09, 2025

Apr 09, 2025

Bausch Health secures intent for acne treatment coverage - Investing.com Australia

Apr 09, 2025

Apr 09, 2025

Bausch Health, Canada Inc. and the pan-Canadian Pharmaceutical Alliance Sign Letter of Intent for Public Drug Plan Coverage of (Pr)CABTREO(TM) (clindamycin phosphate, adapalene and benzoyl peroxide gel) Treatment for Acne Vulgaris - Yahoo Finance

Apr 09, 2025

Apr 09, 2025

Bausch Health Companies Unit Entered Into A New Senior Secured Credit Agreement - MarketScreener

Apr 09, 2025

Apr 08, 2025

Ophthalmology Market Report 2025 | Industry to Reach US$93.7 Billion by 2030 | Emerging Research Activities of Ophthalmology Treatments and Availability of Grants Present Business Opportunities - GlobeNewswire Inc.

Apr 08, 2025

Apr 08, 2025

Bausch Health Misses Revenue Estimates, RBC Analysts React - Finimize

Apr 08, 2025

Apr 07, 2025

Bausch Health Faces Revenue Miss And Price Target Cut - Finimize

Apr 07, 2025

Apr 07, 2025

Alex Meruelo Reports 9.99% Stake In Bausch Health Companies Inc As Of March 31SEC Filing - MarketScreener

Apr 07, 2025

Apr 07, 2025

Sector Update: Health Care Stocks Slipping in Late Afternoon Trading - MarketScreener

Apr 07, 2025

Apr 07, 2025

Bausch Health Faces Challenges Amid Price Target Downgrade - Evrim Ağacı

Apr 07, 2025

Apr 07, 2025

Bausch Health stock target cut to $8.50 by RBC Capital - Investing.com South Africa

Apr 07, 2025

Apr 07, 2025

RBC Previews Bausch Health's Q1 - MarketScreener

Apr 07, 2025

Apr 07, 2025

RBC Capital Adjusts PT on Bausch Health Companies to $8.50 From $9, Keeps Sector Perform Rating - MarketScreener

Apr 07, 2025

Apr 05, 2025

Bausch Health: Repositioning Aplezin As First Oral Monotherapy For TRD A $3 Billion Opportunity - Seeking Alpha

Apr 05, 2025

Apr 03, 2025

SHAREHOLDER ALERT: Potential Recovery for Bausch Health Companies Inc. (BHC) Investors Affected by Stock Drop – Levi & Korsinsky Pursuing Class Action Lawsuit - ACCESS Newswire

Apr 03, 2025

Apr 03, 2025

Bausch Health Companies Becomes Oversold (BHC) - Nasdaq

Apr 03, 2025